The global pharmaceutical supply chain has seen significant volatility in 2025, and Diphenhydramine Hydrochloride—a widely used H1 antihistamine—has not been immune. In North America, Q2 2025 witnessed a notable upward trend in prices, largely driven by global supply tightness, rising import costs from Asia, and strong domestic demand. This article explores the dynamics behind these movements, focusing on North America while providing context from the Asia-Pacific and European markets.
Track Real